학술논문

Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England
Document Type
Academic Journal
Source
International Journal of Chronic Obstructive Pulmonary Disease. September 30, 2021, Vol. 16, p2591, 14 p.
Subject
United Kingdom
Language
English
ISSN
1178-2005
Abstract
Background: Available data on the relationship between COPD symptoms, disease outcomes, and mortality are currently limited. This study investigated the clinical characteristics, outcomes, healthcare utilization, and prescribing practices across GOLD 2017 groups (A, B, C, and D) in a large-scale, population-based cohort of COPD patients managed in an English primary care setting. Patients and Methods: This retrospective analysis included patients aged [greater than or equal to] 35 years, with a confirmed diagnosis of COPD and [greater than or equal to] 1 record of pulmonary function testing in their medical history. Medical Research Council dyspnea score and exacerbation history were used to define patients' GOLD 2017 classification. Patients were identified using the UK Clinical Practice Research Database and were followed for 12 months. Results: Eligible COPD patients' (N=42,331; mean [SD] age, 69.5 [10.7] years; 54% males), GOLD 2017 categorizations were: Group A: 49.1%, Group B: 30.5%, Group C: 8.2%, Group D: 12.1%. Overall, 37.7% of patients experienced [greater than or equal to] 1 moderate COPD exacerbation. The rate of moderate exacerbations per person per year (PPPY) was highest in GOLD group D (0.72), followed by C (0.53), B (0.22), and A (0.15), while the rate of exacerbations leading to hospitalization PPPY was much higher in D (0.27) than in B (0.10), C (0.08), or A (0.03). Overall, 56.4% of patients visited their general practitioner [greater than or equal to] 5 times in the 12 months of follow-up. Time-to-event analysis suggested that breathlessness contributed to exacerbation severity and frequency. One-year mortality was highest in GOLD groups D and B. The most frequent prescribed maintenance therapies were inhaled corticosteroids with long-acting [[beta].sub.2]-agonists, multiple-inhaler triple therapy, or long- acting muscarinic antagonist, irrespective of GOLD classification. Conclusion: The burden of COPD remains substantial in England. Stratification of this large primary care population according to GOLD criteria predicted the risk of COPD exacerbations. Understanding populations of patients with COPD may enable the optimization of patient care. Keywords: chronic obstructive lung disease, database, exacerbations, healthcare costs, Global Initiative for Chronic Obstructive Lung Disease, maintenance therapy
Introduction Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality that presents a significant burden on healthcare systems and resources worldwide, (1) including healthcare costs. (2) [...]